Review
Post ScreenExploiting the enhanced permeability and retention effect for tumor targeting
Post Screen
Section snippets
The theory behind enhanced permeability and retention, pathophysiology and anatomy of tumor vasculature
When tumor cells multiply, cluster together and reach a size of 2–3 mm angiogenesis is induced, to cater for the ever-increasing nutrition and oxygen demands of the growing tumor [3]. This neovasculature differs greatly from that of normal tissues in microscopic anatomical architecture [4]. For instance, the blood vessels in the tumor are irregular in shape, dilated, leaky or defective, and the endothelial cells are poorly aligned or disorganized with large fenestrations. Also, the perivascular
Vascular endothelial growth factor
Vascular permeability factor (VPF) [15], identical to vascular endothelial growth factor (VEGF), has a significant role in tumor angiogenesis 16, 17. In addition to being a mitogen for endothelial cells, it plays a pivotal role in tumor growth and, perhaps, in metastasis because of its induction of vascular permeability [15]. Increased vascular permeability will lead to an enhanced extravasation of macromolecules. Besides VEGF, the EPR effect is further amplified by numerous other vascular
Angiotensin-II-induced hypertension
The vascular density of many, if not all, tumors is higher than that of normal tissues. Further, tumor blood vessels lack a smooth-muscle layer, which plays a vital role in regulating blood pressure and flow. In normal blood vessels, the smooth-muscle layer responds to vascular mediators such as BK, acetylcholine, NO and calcium via receptors on vascular smooth-muscle cells, helping to maintain constant blood flow volume. In normal tissues, when hypertension is induced by infusing
Prolonging half-life, stealth-character and reduced antigenicity
Because accumulation of macromolecules by the EPR effect is a progressive phenomenon, it is essential that the drugs are stable in plasma for long time periods. In addition to prolonging the half-life in plasma of low-molecular-weight drugs or proteins, polymer conjugation also guides the drugs to their target by the EPR effect [51]. It also confers stealth character and suppresses antigenicity of the proteinaceous drugs, as well as diminishing uptake by the reticuloendothelial system (RES) or
The SMANCS–polymer conjugate of copoly(styrene maleic-acid) with neocarzinostatin
The first prototype macromolecular anticancer agent, SMANCS, developed in our group, was approved for clinical use in Japan in 1993. The plasma half-life of SMANCS is ∼20 times longer than that of native NCS 2, 14, 38, 46. Further, NCS increased lipid solubility after conjugation with SMA, which enabled administration of SMANCS together with the lipid contrast agent Lipiodol®. SMANCS–Lipiodol® (injected via the tumor-feeding artery) resulted in drug retention >2000-fold higher in tumor tissue
Conclusion
The EPR effect is commonly observed in most solid tumors, either primary or metastatic in nature. The EPR effect is modulated or mediated by various factors produced by tumor cells, infiltrating leukocytes or even tumor-surrounding normal cells.
Obviously, many vascular mediators, such as BK, PGs and NO, also affect normal blood vessels near tumor tissue. Also, vascular density and microanatomical defects play important roles in this phenomenon. The EPR effect will confer most macromolecular and
References (80)
Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier
Eur. J. Cancer
(1995)Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS
J. Control. Release
(2001)Bradykinin and nitric oxide in infectious disease and cancer
Immunopharmacology
(1996)Purification and identification of [hydroxypropyl 3] bradykinin in ascetic fluid from a patient with gastric cancer
J. Biol. Chem.
(1988)Kallikrein-kinin in infection and cancer
Immunopharmacology
(1999)Superoxide generation mediated by 8-nitroguanosine, a highly redox-active nucleic acid derivative
Biochem. Biophys. Res. Commun.
(2003)Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation
J. Biol. Chem.
(2001)SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy
Adv. Drug Deliv. Rev.
(2001)Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications
Int. Immunopharmacol.
(2003)SMA-doxorubicin, a new polymeric micellar drug for effective targeting to solid tumours
J. Control. Release
(2004)
Polymer conjugates: nanosized medicines for treating cancer
Trends Biotechnol.
Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME)
Int. J. Pharm.
Pegaspargase: a review of clinical studies
Adv. Drug Deliv. Rev.
Respiratory toxicity of multi-wall carbon nanotubes
Toxicol. Appl. Pharmacol.
Liposomes as vehicles for targeted therapy of cancer. Part 2: clinical development
Clin. Oncol. (R Coll Radiol)
Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome
J. Control. Release
Synthesis of angiogenesis-targeted peptide and hydrophobized polyethylene glycol conjugate
Bioorg. Med. Chem. Lett.
Why we’re losing the war on cancer (and how to win it)
Fortune
A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumor tropic accumulation of proteins and antitumor agent SMANCS
Cancer Res.
Angiogenesis in cancer, vascular, rheumatoid and other disease
Nat. Med.
Microvascular architecture of experimental colon tumors in the rat
Cancer Res.
A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II
J. Natl. Cancer Inst.
Tumoritropic and lymphotropic principles of macromolecular drugs
Crit. Rev. Ther. Drug Carrier Syst.
Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image
Cancer Res.
The origin of lipoproteins in lymph
Enhanced permeability and retention (EPR) effect and tumor-selective delivery of anticancer drugs
Polymer therapeutics for cancer: current status and future challenges
Adv. Polym. Sci.
Polycefin, a new prototype of a multifunctional nanoconjugate based on poly (beta-l-malic acid) for drug delivery
Bioconjug. Chem.
Early phase of tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues
Jpn. J. Cancer Res.
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
Science
Conditioned medium from mouse sarcoma 180 cells contains vascular endothelial growth factor
Growth Factors
Vascular endothelial growth factor is a secreted angiogenic mitogen
Science
Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger
Cancer Res.
Involvement of the kinin-generating cascade and enhanced vascular permeability in tumor tissue
Jpn. J. Cancer Res.
Excessive production of nitric oxide in rat solid tumor and its implication in rapid tumor growth
Cancer
Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases
Jpn. J. Cancer Res.
Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor
Jpn. J. Cancer Res.
Involvement of the kinin-generating cascade in enhanced vascular permeability in tumor tissue
Jpn. J. Cancer Res.
Kinin-generating cascade in advanced cancer patients and in vitro study
Jpn. J. Cancer Res.
Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues
Int. J. Cancer
Cited by (1613)
Recent advancements in Nanotechnology-Mediated Platinum-Based cancer therapy
2024, Coordination Chemistry ReviewsFrom the clinical perspective of photodynamic therapy and photothermal Therapy: Structure-Activity-Practice
2024, Coordination Chemistry ReviewsDesign strategies for aggregation-induced emission photosensitizers with enhanced safety in photodynamic therapy
2024, Coordination Chemistry ReviewsCutting-edge advancements in anticancer drug delivery and scope for theranostics using biocompatible multifunctional mesoporous silica nanoparticles
2024, Journal of Drug Delivery Science and TechnologyNanocrystal technologies in biomedical science: From the bench to the clinic
2024, Drug Discovery TodayOvercoming drug resistance with specific nano scales to targeted therapy: Focused on metastatic cancers
2024, Pathology Research and Practice